Cartography Biosciences has secured $67 million in Series B funding to advance its pioneering oncology therapies, a significant step for a company focused on developing T-cell engaging bispecific antibodies. This investment will enable the progression of their lead program, CBI-1214, and accelerate the development of other innovative treatments targeting specific tumor antigens, addressing critical needs in cancer care.
SAN FRANCISCO–(BUSINESS WIRE)–Cartography Biosciences, Inc., an oncology company advancing an innovative pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics that target novel and highly specific tumor antigens, today announced the close of a $67 million Series B financing. The funding will help support the advancement of Cartography’s lead program, CBI-1214, into the clinic and the continued acceleration of additional, highly differentiated oncology programs genera
Source: Original Press Release
